橫店東磁(002056.SZ):年產1.48億支高性能鋰電池項目投產
格隆匯8月16日丨橫店東磁(002056.SZ)公佈,此前披露,公司於2020年10月22日召開的第八屆董事會第七次會議審議通過了《公司關於投資年產1.48億支高性能鋰電池項目的議案》,項目投資估算61238萬元,其中新增固定資產投資49238萬元,新增流動資金12000萬元。項目建成投產後預計可實現年新增銷售收入80330萬元,年利潤總額11077萬元。
目前,該項目已基本建設完成並投入生產。 該項目符合公司“發展能源”的戰略部署,全面達產後鋰電池總產能約為2.5GWh。隨着新建產能的逐步釋放,將進一步提升公司鋰電池產業的市場競爭力及盈利能力,從而增強公司鋰電池產業的發展後勁。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.